



Council of the  
European Union

Brussels, 23 July 2014  
(OR. en)

12132/14  
ADD 1

DENLEG 134  
AGRI 510  
SAN 294

#### COVER NOTE

---

From:	European Commission
date of receipt:	22 July 2014
To:	Mr Uwe CORSEPIUS, Secretary-General of the Council of the European Union

---

No. Cion doc.:	D029597/03 - Annex 1
Subject:	ANNEX to the COMMISSION REGULATION (EU) No .../.. refusing to authorise certain health claims made on foods, other than those referring to the reduction of disease risk and to children's development and health

---

Delegations will find attached document D029597/03 - Annex 1.

---

Encl.: D029597/03 - Annex 1



Brussels, **XXX**  
SANCO/11586/2013 Rev. 2 ANNEX  
(POOL/E4/2013/11586/11586R2-EN  
ANNEX.doc) D029597/03  
[...] (2014) **XXX** draft

ANNEX 1

**ANNEX**

**to the**

**COMMISSION REGULATION (EU) No .../..**

**refusing to authorise certain health claims made on foods, other than those referring to  
the reduction of disease risk and to children's development and health**

## ANNEX

### Rejected health claims

<b>Application – Relevant provisions of Regulation (EC) No 1924/2006</b>	<b>Nutrient, substance, food or food category</b>	<b>Claim</b>	<b>EFSA opinion reference</b>
Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data	Zinc	Prevents bad breath by neutralising of volatile sulphur compounds (VSC) in the mouth and oral cavity.	Q-2010-01092
Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data	Yestimun <sup>®</sup>	Daily administration of Yestimun <sup>®</sup> helps to maintain the body's defence against pathogens.	Q-2012-00761
Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data	Transitech <sup>®</sup>	Improves transit and durably regulates it.	Q-2013-00087
Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data	Bimuno <sup>®</sup> GOS	Regular daily consumption of 1.37 g galacto-oligosaccharides from Bimuno <sup>®</sup> may reduce abdominal discomfort.	Q-2012-01007
Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data	<i>Lactobacillus rhamnosus</i> GG	<i>Lactobacillus rhamnosus</i> GG for maintaining normal defecation during oral antibiotic treatment.	Q-2013-00015

Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data	VeriSol®P	Characteristic collagen peptide mixture (collagen hydrolysate) having a beneficial physiological effect on the maintenance of skin health, as indicated by an increased skin elasticity and a reduction of wrinkles volume, by contributing to a normal collagen and elastin synthesis.	Q-2012-00839
Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data	Proanthocyanidins in Urell®	Proanthocyanidins from Urell® contribute to support defence against bacterial pathogens in the lower urinary tract	Q-2012-00700
Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data	Preservation®	Improves the physiological response to stress by accelerating the appearance of heat shock proteins (HSPs) and maintains an effective level of HSPs to ensure that the organism is primed should the cell encounter further stress.	Q-2013-00021